BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Evolva A/S to Receive First Milestone Payment from Roche (RHHBY)


6/14/2011 9:28:41 AM

Reinach, Switzerland, 14 June 2011 – Evolva Holding SA (SIX: EVE) today announced that Roche (SIX: ROG, RO; OTCQX: RHHBY) has confirmed that Evolva has achieved its first milestone in their collaboration. Roche will now make a corresponding milestone payment (of an undisclosed amount) to Evolva. The milestone relates to the achievement of diverse, purified active compounds that derive from Evolva’s synthetic biology platform. The milestone payment does not change Evolva’s cash flow guidance for 2011.

The aim of Evolva’s collaboration with Roche is to use Evolva’s technology platform to create compounds with activity on targets in oncology and infectious disease. The project commenced in January 2010.

Neil Goldsmith, CEO and Managing Director of Evolva, said “The collaboration with Roche is progressing well. Our platform is delivering on its promise to fundamentally change multiple industries. After recent successes in nutritional ingredients, it is great to see the potential in pharmaceuticals further confirmed.”

About the Roche discovery collaboration

The programme was initiated in January 2010 and focuses on creating compounds with activity on targets in oncology and infectious disease using Evolva’s technology platform. Roche has paid Evolva an up-front technology access fee and is paying research fees during the project. Roche will have responsibility to take forward any compounds discovered during the collaboration and will potentially pay Evolva research and clinical milestone fees as well as royalties on any products that result from the collaboration. Evolva will have the first right to any compounds not taken forward, or subsequently deprioritised by Roche.

About Evolva

Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. For more information visit www.evolva.com.

Contact Details

Evolva

Neil Goldsmith, CEO

neilg@evolva.com

+ 41 61 485 2005

Jakob Dynnes Hansen, CFO

jakobdh@evolva.com

+ 41 61 485 2034

Paul Verbraeken, IR

paulv@evolva.com

+ 41 61 485 2035

Capital MSL

Mary Clark, Justine Lamond and Hollie Vile

evolva@capitalmsl.com

+44 (0)20 7307 5337



Read at BioSpace.com

Evolva A/S
Roche
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES